Cingulate Inc. (CING) Quarterly EPS earnings growth

cingulate.com - graphic logo of issuer CING

Quarterly net income per share growth rates reflect the impact of inflationary risks and logistics costs, with the metric reaching 59.50. The success of Cingulate Inc. (CING) is tied to the approval of ADHD medications and the rigor of psychotropic controls. Biotech experts lead the team, striving for transparency with the FDA. Laboratory robots and predictive software are being implemented to ensure the accuracy of molecule screening.

Cingulate (CING) - Year-over-year earnings per one share growth for the last 12 months from 07/04/2022 to 11/10/2026

Analytical breakdowns and data insights for company Cingulate Inc. (CING)

- share price and consensus valuation forecast:
Stock Quotes cingulate.com|CING - Average Forecast Price
- market capitalization details:
Market Capitalization Cingulate Corp|CING - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share Cingulate|CING - Accounting Value of Company|Market Value to Book Value Ratio cingulate.com|CING - Company Assets
- debt and liquidity details:
Total Debt to Capital Cingulate Inc.|CING - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital cingulate.com|CING - Company Total Debt Obligations|Debt to Book Capitalization Ratio Cingulate Corp|CING - Company Long-Term Indebtedness|Company Short-Term Debts Cingulate|Quick Liquidity Indicator cingulate.com
- earnings and valuation multiples indicators:
CING - Net Profit|Expected Profit Cingulate Inc.|CING - Price to Earnings Ratio|Forward P/E Multiple cingulate.com|CING - PEG Multiple|Enterprise Value to EBITDA Ratio Cingulate Corp|CING - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Cingulate|CING - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months cingulate.com|CING - Earnings per share increase in current year|Earnings growth forecast for next year Cingulate Inc.
Analysis of all company metrics:Cingulate Inc.
Flagship merchandise of Cingulate Inc.

For Cingulate Inc. (CING), which protects the ADHD market with CTR technology patents, the quarterly EPS trend serves as an indicator of intellectual property monetization and cost management efficiency. This metric measures the percentage change in net income per share relative to the same period last year, allowing investors to use this chart to assess the sustainability of business capitalization rates across different cycle phases.

Key competitors

ALKS (Alkermes) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Avadel Pharmaceuticals PLC (AVDL)|ATAI (atai Life Sciences Corp) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months GH Research Group (GHRS)|Quarterly EPS earnings growth MNMD|CMPS (compasspathways.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months LB Pharmaceuticals LBRX|Bright Minds Bio (DRUG) - Earnings per share growth in annualized terms for the last twelve months|Vanda Pharmaceuticals Inc - Quarterly EPS earnings growth|Cybin Inc. (CYBN) - Year-over-year net earnings per share growth for the last 12 months|ANRO: Quarterly EPS earnings growth|NRXP - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Silo Pharma|Year-over-year earnings per share growth for the last 12 months CPHI (China Pharma)|Quarterly EPS earnings growth CMND|Psyence Bio (PBM) - Net earnings per share growth for the trailing year|SciSparc Ltd - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth seelostherapeutics.com SEEL|VRPX - Year-over-year earnings per share growth for the last twelve months|KRTX: Year-over-year earnings per share growth for the last twelve months